I"n<div class="row justify-content-between">
<div class="col-md-8 pr-5 about-us">

<h3>TomorrowScale Ventures</h3>
<p>TomorrowScale Ventures is an early stage venture capital fund backing life science and deep technology startups. We select for exceptional scientific and technical founding teams solving important challenges at the frontiers of science and medicine. Then we partner with and support them from insight to exit velocity, and beyond.</p> 
<br />
<h3>TomorrowScale Podcast</h3>

<p>To tackle the biggest problems and build the leading science-based companies, we must explore stories from the scientists and entrepreneurs on the benches and in the trenches of R&amp;D. </p><br /><p>Justin Briggs, TomorrowScale's creator and host, is a scientist, entrepreneur, and investor based in the Central United States, here because of an interest in scientific discovery, entrepreneurship, and a desire to learn directly from peers and leaders regardless of geography.</p>

<blockquote>These are stories from the cutting edge of science and medicine.</blockquote>

<h3>What is "TomorrowScale?"</h3>

<p>In 2019, based on a drive to work on difficult scientific problems, and an interest in many scientific domains, the scientists that conduct research on the frontiers of physics and biomedicine, and the companies that validate and commercialize them, Justin founded TomorrowScale. The TomorrowScale podcast is a series of conversations with the scientists and entrepreneurs who are building the future.</p>

<p>In December 2021, the TomorrowScale Podcast became affiliated with TomorrowScale Ventures. In 2022, we will return with more and bigger, better content. Stay tuned.</p>

<h4>Creator &amp; Host</h4>

<p><a target="_blank" href="https://linkedin.com/in/briggsly">Justin Briggs</a> is the founder of TomorrowScale, host of the TomorrowScale Podcast, and managing partner of <a target="_blank" href="https://tomorrowscalevc.com">TomorrowScale Ventures</a>.</p>

<p>Justin works at the nexus of biology, chemistry, engineering, and technology, has worked on both sides of the table at two leading venture accelerators, and has worked on drug development and technology commercialization for the last 15 years. In that time, he has been involved as a founder, investor, advisor, or team member for more than two dozen biotech, nanotech, robotics, energy, agriculture, hardware, and software companies, and gained experience across a wide range of development and commercialization activities relevant to early-stage science based companies.</p>

<p>Justin also currently serves as Senior Director at <a target="_blank" href="https://tetherex.com">Tetherex</a>, a clinical-stage biopharmaceutical company pursuing biologic therapeutics and vectored vaccines for inflammatory, oncologic, and infectious diseases. Tetherex has multiple clinical readouts in 2022 for its programs, and the company is open to discussing serious partnering inquiries.</p>

<p>Previously, Justin served as a Venture Partner at <a target="_blank" href="https://deepscienceventures.com">Deep Science Ventures</a>, a London-based venture studio and laboratory for building optimimal scientific ventures. At DSV, Justin supported their growing portfolio of leading life science and deep technology startups founded through the DSV program. Located in nearly 20 countries, these startups count LowerCarbon Capital, LifeArc, Grantham Foundation, Stripe, Schmidt Futures, and YCombinator (among others) as investors.</p>

<p>Prior to Tetherex, Justin worked on both sides of the table at a biotech venture accelerator and venture capital fund, serving as Vice President of Business Development and Operations at Accele BioPharma and Associate at Accele Venture Partners. Accele identified, funded, and managed novel therapeutic and diagnostic startups, including programs to: regenerate beta cells in the pancreas for diabetes; regenerate neurons and hair cells for hearing loss and balance disorders; discover fully human antibodies for cancer, infectious, and neglected disease treatments and diagnostics; and, discover novel antibiotics against multi-drug resistant organisms. Before Tetherex, Justin spent seven years developing a novel combination treatment for ulcerative colitis from the bench through phase 2 studies. Justin also founded SnapLap Technologies (machine vision AI for energy exploration) and Chorus Labs (enterprise collaboration software) and is an inventor and author on multiple patents and peer-reviewed publications.</p>

<h4>Connect with TomorrowScale Ventures</h4>

<p>Any research or startups we should hear about? Let us know!</p>

<p>We are looking to support and connect scientists and engineers to opportunities (backing or employment) in high growth science-based startups. We'd love to chat and learn about your science and vision for the future. Send us an <a href="mailto:justin@tomorrowscale.com?subject=TomorrowScale+Inquiry">email</a>.</p>

</div>
</div>
:ET